The company has axed 80% of its staff and is considering a wind-down after the out-licencing deal of its lead antifungal was ...

Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) missed analyst estimates by 40%. Looking ahead, revenue ...

After hours: November 4 at 5:39 PM EST Loading Chart for LSB ...

*For more details about COVID-19 therapeutics and vaccines, diagnostic products and clinical trial delays, go to BioWorld Snapshots.

ASX swings wildly, with Quickstep and Sigma Healthcare in the spotlight, while Wall Street hits record highs following ...

Bruce, Professional Relations Associate, 3M Pharmaceuticals, personal communication, March 2007). Of interest to us were the four subjects (15%) with reactions to fragrance mix. The positive ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Reports Q3 revenue $175.7M, consensus $157.3M. The company said, “For the third quarter and first nine months of 2024, strong performance ...

Q3 2024 Earnings Call Transcript November 4, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.38, expectations were $4.14. Operator: Good day. And welcome to ...

Merko Ehitus Eesti, part of the Merko Ehitus group, has entered into a design-and-build construction contract with the Estonian Centre for Defence Investment for the construction of a National Defence ...